<DOC>
	<DOCNO>NCT02965170</DOCNO>
	<brief_summary>Validating peptide-based laboratory test enable measurement Tysabri® serum level ( pharmacokinetics , PK ) multiple sclerosis patient undergoing therapy . The result newly develop test compare Tysabri® serum level measure parallel use independent test . We also simultaneously measure pharmacodynamic marker Tysabri® , receptor saturation level blood immune cell , think correlate Tysabri® serum level .</brief_summary>
	<brief_title>Validation Laboratory Test Measuring Natalizumab ( Tysabri® ) Serum Levels MS</brief_title>
	<detailed_description>From single site , consent patient relapse form multiple sclerosis currently begin treat Tysabri® ( natalizumab ) meeting eligibility criterion ask provide blood sample day , prior , schedule infusion Tysabri® 300 mg IV . Up 500 patient enrol study . Each patient may ask donate blood 2 time ( one blood draw per cycle ) obtain longitudinal data point . Each patient also ask fill wellness patient report outcome ( PRO ) questionnaire along blood draw</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Infusing Tysabri single site , Rocky Mountain MS Clinic If subject donate received blood , plasma , blood product last Tysabri® infusion time sample collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>